Biosimilars Surveillance Program Gears Up For Infliximab And Insulin
This article was originally published in The Pink Sheet Daily
Executive Summary
With preliminarily Zarxio data expected shortly, consortium of payers and sponsors is laying groundwork to monitor future biosimilar launches.
You may also be interested in...
Biosimilar Suffix Detractors Hope Private Studies Build Their Case
Consortium’s biosimilar pharmacovigilance could provide data foundation to pressure FDA that suffixes are not needed in non-proprietary names.
Biosimilar Suffix Detractors Hope Private Studies Build Their Case
Consortium’s biosimilar pharmacovigilance could provide data foundation to pressure FDA that suffixes are not needed in non-proprietary names.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.